e6vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of November
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrants name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrants security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If Yes is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Oncolytics
Biotech Inc.
(Registrant) |
|
|
|
|
|
|
|
Date November 14, 2005 |
|
By: |
|
/s/ Doug Ball
Doug Ball
Chief Financial Officer |
|
|
|
|
|
210, 1167 Kensington Cr. N.W |
|
Calgary, Alberta |
|
Canada T2N 1X7 |
For Immediate Release
Oncolytics Biotech Inc. to Webcast
Clinical Trial Update for REOLYSIN®
CALGARY, Alberta, - November 14, 2005 Dr. Brad Thompson, President and CEO of Oncolytics
Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will host a webcast at 8:30 a.m. EST on Thursday, November
17, 2005 to provide a clinical trial update for REOLYSIN®, with a particular focus on the
information being presented this week at the AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics being held in Philadelphia, Pennsylvania.
Two poster presentations by Oncolytics collaborators will be delivered at the AACR-NCI-EORTC
conference. A poster entitled Reovirus enhances radiation cytotoxicity in vitro and in vivo will
be presented Tuesday, November 15, 2005 by Dr. Kevin J. Harrington of the Targeted Therapy
Laboratory, The Institute of Cancer Research, Cancer Research UK Centre for Cell and Molecular
Biology, UK. A second poster entitled A Phase I study of a wild-type reovirus (Reolysin) given
intravenously to patients with advanced malignancies will be presented on Thursday, November 17,
2005 by Dr. Johann S. de Bono of The Royal Marsden Hospital and The Institute of Cancer Research,
UK. Abstracts of these presentations will be available on the AACR website on Monday, November 14,
2005. The posters will be available on the Companys homepage at www.oncolyticsbiotech.com on
November 15 and 17, 2005 respectively.
The live audio webcast will be available at:
http://w.on24.com/r.htm?e=17899&s=1&k=A0A05B5477B6AD312BCAEBE40FBB6D79
or through www.oncolyticsbiotech.com. Please connect to the link at least 15 minutes
prior to the webcast to ensure adequate time for any software download that may be needed. A replay
of the webcast will be available at www.oncolyticsbiotech.com until December 1, 2005, and will also
be available by telephone through November 24, 2005. To access the telephone replay, dial
1-416-640-1917 or 1-877-289-8525 and enter reservation number 21163310.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN®, its
proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics
researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in
vitro, kill human cancer cells that are derived from many types of cancer including breast,
prostate, pancreatic, bladder and brain tumours, and have also demonstrated successful cancer
treatment results in a number of animal models. Phase I clinical trial results have indicated that
REOLYSIN® was well tolerated and that the reovirus demonstrated activity in tumours injected with
REOLYSIN®.
The webcast time is subject to change. This release and the presentation related thereto
contain forward-looking statements which involve known and unknown risks, delays, uncertainties and
other factors not under the Companys control and which may cause actual results, performance or
achievements of the Company to be materially different from the results, performance or
expectations implied by these forward-looking statements. Such risks and uncertainties include,
among others, the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of
clinical studies and trials, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general changes to the
economic environment. Investors should consult the Companys quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward looking statements. Investors are cautioned against placing undue reliance
on forward looking statements. The Company does not undertake to update these forward looking
statements
FOR FURTHER INFORMATION PLEASE CONTACT:
|
|
|
Oncolytics Biotech Inc.
|
|
The Equicom Group |
Cathy Ward
|
|
Joanna Longo |
210, 1167 Kensington Cr NW
|
|
20 Toronto Street |
Calgary, Alberta T2N 1X7
|
|
Toronto, Ontario M5C 2B8 |
Tel: 403.670.7377
|
|
Tel: 416.815.0700 ext.233 |
Fax: 403.283.0858
|
|
Fax: 416.815.0080 |
www.oncolyticsbiotech.com
|
|
jlongo@equicomgroup.com |
|
|
|
The Investor Relations Group
|
|
RenMark Financial Communications |
John Nesbett or Damian McIntosh
|
|
John Boidman |
11 Stone St, 3rd Floor
|
|
2080 Rene Levesque Blvd. W. |
New York, NY 10004
|
|
Montreal, PQ H3H 1R6 |
Tel: 212.825.3210
|
|
Tel: 514.939.3989 |
Fax: 212.825.3229
|
|
Fax: 514.939.3717 |
dmcintosh@investorrelationsgroup.com
|
|
jboidman@renmarkfinancial.com |
-30-